Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cardiac failure acute02.05.01.0050.000052%Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cardiac hypertrophy02.04.02.0170.000035%Not Available
Cardiac tamponade02.06.01.0010.000052%
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000245%Not Available
Cardiogenic shock24.06.02.006; 02.05.01.0030.000070%Not Available
Cardiomegaly02.04.02.0010.000122%Not Available
Cardiomyopathy02.04.01.0010.000227%Not Available
Cataract06.06.01.0010.000489%
Cataract subcapsular06.06.01.0020.000070%Not Available
Catatonia19.11.01.0010.000140%Not Available
Cerebellar infarction24.04.06.007; 17.08.01.0130.000070%Not Available
Cerebral atrophy17.11.01.0010.000157%Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.0030.000262%Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.000524%Not Available
Cerebral ischaemia17.08.01.005; 24.04.06.0030.000052%
Cerebral venous thrombosis24.01.04.005; 17.08.03.0020.000157%Not Available
Cerebrovascular disorder17.08.02.002; 24.03.05.0020.000070%Not Available
Cervical dysplasia21.06.01.0020.000077%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.000734%Not Available
Choking sensation22.12.03.004; 19.01.02.0020.000035%Not Available
Cholangiocarcinoma09.04.02.009; 16.07.01.0020.000140%Not Available
Cholangitis09.02.01.0020.000035%Not Available
Cholecystitis09.03.01.0010.000070%
Cholecystitis acute09.03.01.0030.000070%Not Available
Cholecystitis chronic09.03.01.0040.000035%Not Available
Cholestasis09.01.01.0010.000175%Not Available
Chorea17.01.01.0010.000105%Not Available
Choreoathetosis17.01.01.0030.000035%Not Available
Chronic fatigue syndrome11.07.01.020; 08.01.01.0130.000035%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene